1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lonsurf Hits Phase III OS Target In Gastric Cancer Study

 
• By John Davis

An improvement in overall survival seen in the Phase III TAGS study and a unique mechanism of action augurs well for Taiho/Servier's Lonsurf gaining gastric cancer as an additional indication, but future competitive pressures are likely to be intense in this therapeutic sector.  

Helicobacter pylori
H pylori infection may precede the development of stomach cancer • Source: Shutterstock

French multinational Servier SA, may have moved a step closer to realizing its ambitions in oncology with positive top-line results emerging from the pivotal Phase III TAGS study, that is evaluating the oral anticancer therapy, Lonsurf (trifluridine plus tipiracil), in patients with gastric cancer. But research into better therapies for gastric cancer is intense, so future success is not a foregone conclusion.

Servier and the Otsuka subsidiary, Taiho Pharmaceutical Co. Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D